Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3011-3019

  Rower, Joseph E ^a   Meditz, Amie ^b   Gardner, Edward M ^b,c   Lichtenstein, Kenneth ^d   Predhomme, Julie ^a   Bushman, Lane R ^a   Klein, Brandon ^a   Zheng, Jia Hua ^a   MaWhinney, Samantha ^a   Anderson, Peter L ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c DENVER PUBLIC HEALTH   (United States)

^d NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; ZIDOVUDINE;

ADULT; AFRICAN AMERICAN; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LEAN BODY WEIGHT; LONGITUDINAL STUDY; MALE; OBSERVATIONAL METHOD; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE;

ADULT; AFRICAN AMERICANS; ANTI-HIV AGENTS; CYTIDINE TRIPHOSPHATE; DIDEOXYNUCLEOTIDES; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; SEX FACTORS; THYMINE NUCLEOTIDES; ZIDOVUDINE;

EID: 84861108461     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06337-11     Document Type: Article

References (41)

1. Abbott Laboratories. 2011. Kaletra (lopinavir/ritonavir) package insert. Abbott Laboratories, North Chicago, IL.
2. Abla N, et al. 2008. The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene. J. Pharmacol. Exp. Ther. 325:859-868. (Pubitemid 351724335)
3. Akaike H. 1974. A new look at the statistical model identification. IEEE Trans. Automat. Contr. 19:716-723.
4. Anderson PL, Kakuda TN, Kawle S, Fletcher CV. 2003. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 17:2159-2168. (Pubitemid 37338889)
5. Anderson PL, et al. 2011. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J. Antimicrob. Chemother. 66:240-250.
6. Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV. 2006. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-Infected adults: a pilot study. J. Acquir. Immune Defic. Syndr. 42:441-449. (Pubitemid 44050891)
7. Anderson PL, Rower JE. 2010. Zidovudine and lamivudine for HIV Infection. Clin. Med. Rev. Ther. 2:115-127.
8. Aweeka FT, et al. 2006. The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine. AIDS 20: 1833-1841. (Pubitemid 44358901)
9. Balzarini J. 1994. The metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives. Pharm. World Sci. 16:113-126. (Pubitemid 24142453)
10. Bazzoli C, et al. 2011. Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients. Antimicrob. Agents Chemother. 55:3423-3431.
11. Broder S. 2010. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 85:1-18.
12. Bushman LR, et al. 2011. Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultrasensitive LC-MS/MS detection. J. Pharm. Biomed. Anal. 56:390-401.
13. Cihlar T, Ray AS. 2010. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res. 85:39-58.
14. Deeks SG, et al. 2004. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 104:942-947. (Pubitemid 39038012)
15. Foisy MM, Yakiwchuk EM, Hughes CA. 2008. Induction effects of ritonavir: implications for drug interactions. Ann. Pharmacother. 42: 1048-1059.
16. Furman PA, et al. 1986. Phosphorylation of 3′-azido-3′- deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA 83:8333-8337. (Pubitemid 17182495)
17. Gao W-Y, Shirasaka T, Johns DG, Broder S, Mitsuya H. 1993. Differential phosphorylation of azidothymidine, dideoxycytidine and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J. Clin. Investig. 91:2326-2333. (Pubitemid 23141513)
18. Gao WY, Agbaria R, Driscoll JS, Mitsuya H. 1994. Divergent antihuman immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J. Biol. Chem. 269:12633-12638.
19. Grant RM, et al. 2010. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363:2587-2599.
20. Heald A, et al. 1996. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob. Agents Chemother. 40:1514-1519. (Pubitemid 26169059)
21. Hsu C-H, et al. 2007. Comparison of the phosphorylation of 4′-ethynyl 2′,3′-dihydro-3′-deoxythymidine with that of other anti-human immunodeficiency virus thymidine analogs. Antimicrob. Agents Chemother. 51:1687-1693. (Pubitemid 46744146)
22. Hunsucker SA, Mitchell BS, Spychala J. 2005. The 5′-nucleotidases as regulators of nucleotide and drug metabolism. Pharmacol. Ther. 107:1-30. (Pubitemid 40800406)
23. Jacobsson B, Britton S, Törnevik Y, Eriksson S. 1998. Decrease in thymidylate kinase activity in peripheral blood mononuclear cells from HIV-infected individuals. Biochem. Pharmacol. 56:389-395. (Pubitemid 28473215)
24. Jiang W, et al. 2009. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J. Infect. Dis. 199:1177-1185.
25. Johnson AA, et al. 2001. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J. Biol. Chem. 276:40847-40857. (Pubitemid 37373231)
26. Johnson MA, Moore KHP, Yuen GJ, Bye A, Pakes GE. 1999. Clinical pharmacokinetics of lamivudine. Clin. Pharmacokinet. 36:41-66. (Pubitemid 29056000)
27. Kakuda TN. 2000. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin. Ther. 22: 685-708. (Pubitemid 30451995)
28. Kewn S, Veal GJ, Hoggard PG, Barry MG, Back DJ. 1997. Lamivudine (3TC) phosphorylation and drug interactions in vitro. Biochem. Pharmacol. 54:589-595. (Pubitemid 27404693)
29. Liston HL, Markowitz JS, DeVane CL. 2001. Drug glucuronidation in clinical psychopharmacology. J. Clin. Psychopharmacol. 21:500-515. (Pubitemid 32937433)
30. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. 1996. SAS system for mixed models. SAS Institute, Inc., Cary, NC.
31. Osler M, Stead D, Rebe K, Meintjes G, Boulle A. 2010. Risk factors for and clinical characteristics of severe hyperlactataemia in patients receiving antiretroviral therapy: a case-control study. HIV Med. 11:121-129.
32. Paintsil E, et al. 2011. Determinants of individual variation in intracellular accumulation of anti-HIV nucleoside analog metabolites. Antimicrob. Agents Chemother. 55:895-903.
33. Panel on Antiretroviral Guidelines for Adults and Adolescents. 2011. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, Washington, DC.
34. Podgorska M, Kocbuch K, Pawelczy T. 2005. Recent advances in studies on biochemical and structural properties of equilibrative and concentrative nucleoside transporters. Acta Biochim. Polonica 52:749-758. (Pubitemid 43155002)
35. Pruvost A, et al. 2009. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob. Agents Chemother. 53:1937-1943.
36. Rodriguez JF, Rodriguez JL, Santana J, Garcia H, Rosario O. 2000. Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virus-infected individuals. Antimicrob. Agents Chemother. 44:3097-3100.
37. Rower JE, Klein B, Bushman LR, Anderson PL. 2011. Validation of a sensitive LC/MS/MS method for the determination of zidovudine and lamivudine in human plasma. Biomed. Chromatogr. 26:12-20.
38. Stretcher BN, Pesce AJ, Frame PT, Stein DS. 1994. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 38:1541-1547. (Pubitemid 24203566)
39. Turriziani O, et al. 2005. Thymidine kinase and deoxycytidine kinase activity in mononuclear cells from antiretroviral-naive HIV-infected patients. AIDS 19:473-479. (Pubitemid 40515850)
40. Van Rompay AR, Johansson M, Karlsson A. 2000. Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases. Pharmacol. Ther. 87:189-198.
41. Wester CW, et al. 2007. Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J. Acquir. Immune Defic. Syndr. 46:318-322. (Pubitemid 350287359)